Pfizer, a prominent pharmaceutical company, is well-known for its leadership in public health, especially through its development of the COVID-19 vaccine. The company has made strides in sustainable operations, with a commitment to reducing its carbon footprint and improving the environmental impact of its manufacturing processes. Pfizer’s ESG rating is bolstered by its focus on improving healthcare access and investing in research and development for both treatments and vaccines. However, the company faces criticism regarding the high cost of its medicines, which has raised concerns about accessibility and affordability. Additionally, Pfizer's ESG score is impacted by governance issues, particularly its pricing practices and patent policies. For a comprehensive understanding of Pfizer's ESG efforts, refer to the latest Pfizer ESG report, which provides insights into its health impact and sustainability efforts. Pfizer's approach to ESG is integrated into its operations, with the Board of Directors overseeing its ESG strategy, focusing on social impact, employees, and people. This approach includes efforts to maintain safety, quality, and regulatory compliance across all business practices. Pfizer's ESG reporting covers sustainability, social responsibility, accountability, and transparency, reflecting its governance practices. The company has taken steps to reduce its environmental footprint, focusing on energy efficiency, renewable energy adoption, and waste minimization. In addition, Pfizer works to improve access to healthcare and patient outcomes, guided by its core values. Pfizer incorporates ESG considerations into its enterprise strategy to support sustainable development. Find above the latest esg report from Pfizer which they now call the impact report.